Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. on July 20, 2009. The filing discloses the entry into a material definitive agreement for a non-brokered registered direct offering of common stock.
Key Financial Metrics
- Offering Size: 475,000 shares of common stock.
- Purchase Price: $20.00 per share.
- Gross Proceeds: $9.5 million (calculated as 475,000 shares x $20.00).
- Net Proceeds: Approximately $9.4 million after estimated offering expenses.
- Closing Date: Expected on or about July 24, 2009.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the execution of subscription agreements with certain institutional investors to sell 475,000 shares. This transaction utilizes a shelf takedown from a registration statement on Form S-3 (File no. 333-160251) that became effective on July 17, 2009.
Outlook and Management Commentary
Management expects the transaction to close on or about July 24, 2009. The net proceeds of approximately $9.4 million are intended to support the company's operations, though specific allocation details are not provided in this excerpt. The filing incorporates by reference a press release dated July 20, 2009, for further details.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received.
- Review the Form S-3 (File no. 333-160251) for details on the shelf registration.
- Examine the Form of Subscription Agreement (Exhibit 10.1) for specific terms and conditions.
- Read the full press release (Exhibit 99.1) for management's intended use of proceeds.